Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Breathing01:05

Breathing

60.3K
The process of breathing, inhaling and exhaling, involves the coordinated movement of the chest wall, the lungs, and the muscles that move them. Two muscle groups with important roles in breathing are the diaphragm, located directly below the lungs, and the intercostal muscles, which lie between the ribs. When the diaphragm contracts, it moves downward, increasing the volume of the thoracic cavity and creating more room for the lungs to expand. When the intercostal muscles contract, the ribs...
60.3K
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

208
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
208
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

434
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by...
434
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

224
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
224
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

583
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
583
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

2.5K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>CFTR</i> gene delivery to human airway epithelia using parainfluenza virus 5 amplifying virus-like particles.

Molecular therapy. Nucleic acids·2026
Same author

Optimized AAV capsids robustly transduce airway epithelial cells.

bioRxiv : the preprint server for biology·2026
Same author

Lentiviral-mediated gene complementation to rescue pathogenic ABCA3 variants.

American journal of respiratory cell and molecular biology·2026
Same author

Considerations for early life genetic therapies in cystic fibrosis.

American journal of physiology. Lung cellular and molecular physiology·2026
Same author

Biallelic LAMP3 variants in 5 families with interstitial lung disease: Evidence of a disease-gene association.

Genetics in medicine : official journal of the American College of Medical Genetics·2026
Same author

IL-13 decreases susceptibility to airway epithelial SARS-CoV-2 infection but increases disease severity in vivo via eicosanoid signalling.

EBioMedicine·2025
Same journal

HEALTHY AGING: THE PROMISE, AND PERILS, OF GEROSCIENCE.

Transactions of the American Clinical and Climatological Association·2025
Same journal

TESTOSTERONE AND INSULIN RESISTANCE IN MEN: EVIDENCE FOR A COMPLEX BI-DIRECTIONAL RELATIONSHIP.

Transactions of the American Clinical and Climatological Association·2025
Same journal

REVISITING GLUCAGON ACTION IN DIABETES: IS IT ALL BAD?

Transactions of the American Clinical and Climatological Association·2025
Same journal

IMPLEMENTING HOME-BASED CANCER PREVENTION AND SCREENING: AN OPPORTUNITY FOR EQUITY.

Transactions of the American Clinical and Climatological Association·2025
Same journal

THE GID COMPLEX REGULATES DNA END PROCESSING DURING DNA DOUBLE-STRAND BREAK REPAIR BY NONHOMOLOGOUS END JOINING.

Transactions of the American Clinical and Climatological Association·2025
Same journal

REVOLUTIONIZING TUBERCULOSIS REGIMEN DEVELOPMENT.

Transactions of the American Clinical and Climatological Association·2025
See all related articles

Related Experiment Video

Updated: Sep 12, 2025

Intratracheal Instillation of Stem Cells in Term Neonatal Rats
04:27

Intratracheal Instillation of Stem Cells in Term Neonatal Rats

Published on: May 4, 2020

5.7K

THERAPIES FOR NEONATAL DISEASES OF THE SURFACTANT SYSTEM.

Paul B McCray1

  • 1Iowa City, IA.

Transactions of the American Clinical and Climatological Association
|August 7, 2025
PubMed
Summary
This summary is machine-generated.

Genetic mutations in surfactant proteins (SFTPB, SFTPC) and ABCA3 disrupt lung function. Gene therapies offer potential treatments for these critical respiratory diseases.

More Related Videos

A Minimally Invasive Method for Intratracheal Instillation of Drugs in Neonatal Rodents to Treat Lung Disease
04:21

A Minimally Invasive Method for Intratracheal Instillation of Drugs in Neonatal Rodents to Treat Lung Disease

Published on: August 4, 2021

6.2K
Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
06:15

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus

Published on: March 6, 2019

50.4K

Related Experiment Videos

Last Updated: Sep 12, 2025

Intratracheal Instillation of Stem Cells in Term Neonatal Rats
04:27

Intratracheal Instillation of Stem Cells in Term Neonatal Rats

Published on: May 4, 2020

5.7K
A Minimally Invasive Method for Intratracheal Instillation of Drugs in Neonatal Rodents to Treat Lung Disease
04:21

A Minimally Invasive Method for Intratracheal Instillation of Drugs in Neonatal Rodents to Treat Lung Disease

Published on: August 4, 2021

6.2K
Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
06:15

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus

Published on: March 6, 2019

50.4K

Area of Science:

  • Pulmonary Medicine
  • Genetics
  • Cell Biology

Background:

  • Pulmonary surfactant, produced by alveolar type II (AT2) cells, is essential for infant respiration.
  • Surfactant comprises phospholipids and proteins (SP-B, SP-C), crucial for alveolar function.
  • Mutations in SFTPB, SFTPC, and ABCA3 genes cause severe respiratory distress and interstitial lung diseases.

Purpose of the Study:

  • To explore the genetic basis of surfactant dysfunction.
  • To investigate the potential of genetic therapies for treating related lung diseases.

Main Methods:

  • Analysis of genetic mutations in SFTPB, SFTPC, and ABCA3.
  • Review of current therapeutic strategies and their limitations.
  • Exploration of gene addition and gene editing as potential treatments.

Main Results:

  • Loss-of-function mutations in SFTPB and ABCA3, and dominant mutations in SFTPC, lead to severe respiratory conditions.
  • No specific treatments are currently available for these genetic lung diseases.
  • Genetic therapies present a promising avenue for correcting the underlying molecular defects.

Conclusions:

  • Genetic defects in surfactant production cause significant respiratory morbidity.
  • Gene-based therapeutic strategies hold promise for treating these debilitating lung diseases.